Correction to: Perceptions of statin discontinuation among patients with life-limiting illness (Journal of Palliative Medicine DOI: 10.1089/jpm.2016.0489);Perceptions of Statin Discontinuation among Patients with Life-Limiting Illness

Journal of Palliative Medicine

Volumn 20, Issue 10, 2017, Pages 1098-1103

  Tjia, Jennifer ^a   Kutner, Jean S ^b   Ritchie, Christine S ^c   Blatchford, Patrick J ^b   Bennett Kendrick, Rachael E ^b   Prince Paul, Maryjo ^d   Somers, Tamara J ^e   McPherson, Mary Lynn ^f   Sloan, Jeff A ^g   Abernethy, Amy P ^h   Furuno, Jon P ⁱ  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^g MAYO CLINIC   (United States)

^h FLATIRON HEALTH   (United States)

ⁱ OREGON STATE UNIVERSITY   (United States)

Author keywords

deprescribing; medication discontinuation; statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITION; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DEPRESCRIPTION; DRUG COST; FEMALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; KIDNEY DISEASE; LIFE EXPECTANCY; LIFE LIMITING ILLNESS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MCGILL QUALITY OF LIFE QUESTIONNAIRE; MULTICENTER STUDY (TOPIC); PATIENT ABANDONMENT; PATIENT ATTITUDE; PRIMARY PREVENTION; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY PREVENTION; TERMINAL DISEASE; CHRONIC DISEASE; DECISION MAKING; MIDDLE AGED; NEOPLASM; PATIENT PREFERENCE; PSYCHOLOGY; TREATMENT WITHDRAWAL;

AGED; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DECISION MAKING; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIFE EXPECTANCY; MALE; MIDDLE AGED; NEOPLASMS; PATIENT PREFERENCE; QUALITY OF LIFE; WITHHOLDING TREATMENT;

EID: 85030218630     PISSN: 10966218     EISSN: 15577740     Source Type: Journal    
DOI: 10.1089/jpm.2019.29009.correx     Document Type: Erratum

References (32)

1. Holmes H: Rational prescribing for patients with a reduced life expectancy. Clin Pharmacol Ther 2009;85:103-107.
2. Holmes HM, Todd A: Evidence-based deprescribing of statins in patients with advanced illness. JAMA Intern Med 2015; 175:701-702.
3. Holmes HM, Hayley DC, Alexander GC, et al.: Reconsidering medication appropriateness for patients late in life. Arch Intern Med 2006;166:605-609.
4. Scott IA, Hilmer SN, Reeve E, et al.: Reducing inappropriate polypharmacy: The process of deprescribing. JAMA Intern Med 2015;51:1-8.
5. Cruz-Jentoft AJ, Boland B, Rexach L: Drug therapy optimization at the end of life. Drugs Aging 2012;29:511-521.
6. Reeve E, To J, Hendrix I, Shakib S, et al.: Patient barriers to and enablers of deprescribing: A systematic review. Drugs Aging 2013;30:793-807.
7. Post SG, Stuckey JC, Whitehouse PJ, et al.: A focus group on cognition-enhancing medications in Alzheimer disease: Disparities between professionals and consumers. Alzheimer Dis Assoc Disord 2001;15:80-88.
8. Tjia J, Talebreza S, Reblin M, et al.: Scramble or script: Responding to new Medicare billing for medications in hospice. J Palliat Med 2014;17:1085-1086.
9. Kutner JS, Blatchford PJ, Taylor DHJ, et al.: Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: A randomized clinical trial. JAMA Intern Med 2015;175:691-700.
10. Bain KT, Holmes HM, Beers MH, et al.: Discontinuing medications: A novel approach for revising the prescribing stage of the medication-use process. J Am Geriatr Soc 2008;56:1946-1952.
11. Currow DC, Stevenson JP, Abernethy AP, et al.: Prescribing in palliative care as death approaches. J Am Geriatr Soc 2007;55:590-595.
12. Woodward M, Bird B, Elliott R, et al.: Deprescribing: Achieving better health outcomes for older people through reducing medications. J Pharm Pract Res 2003;33:323-328.
13. Tjia J, Givens J: Ethical framework for medication discontinuation in nursing home residents with limited life expectancy. Clin Geriatr Med 2012;28:255-272.
14. Stevenson J, Abernethy AP, Miller C, et al.: Managing comorbidities in patients at the end of life surveys of in patients at the end of life 2015;329:909-912.
15. Britten N, Stevenson FA, Barry CA, et al.:Misunderstandings in prescribing decisions in general practice: Qualitative study. BMJ 2000;320:484-488.
16. Leydon GM, Rodgers L, Kendrick T: A qualitative study of patient views on discontinuing long-Term selective serotonin reuptake inhibitors. Fam Pract 2007;24:570-575.
17. Tjia J, Givens JL, Karlawish JH, et al.: Beneath the surface: Discovering the unvoiced concerns of older adults with type 2 diabetes mellitus. Health Educ Res 2008;23:40-52.
18. Schuling J, Gebben H, Veehof LJG, et al.: Deprescribing medication in very elderly patients with multimorbidity: The view of Dutch GPs. A qualitative study. BMC Fam Pract 2012;13:56.
19. Scott IA, Anderson K, Freeman CR, et al.: First do no harm: A real need to deprescribe in older patients. Med J Aust 2014;201:390-392.
20. Abernethy AP, Aziz NM, Basch E, et al.: A strategy to advance the evidence base in palliative medicine: Formation of a palliative care research cooperative group. J Palliat Med 2010;13:1407-1413.
21. Abernethy AP, Shelby-James T, Fazekas BS, et al.: The Australia-modified Karnofsky Performance Status (AKPS) scale: A revised scale for contemporary palliative care clinical practice. BMC Palliat Care 2005;4:7.
22. Pfeiffer E: A short portable mental status questionnaire (SPMSQ). J Am Geriatr Soc 1975;23:1975.
23. Charlson ME, Pompei P, Ales KL, et al.: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-383.
24. Cohen SR, Mount BM, Strobel MG, et al.: The McGill Quality of Life Questionnaire: A measure of quality of life appropriate for people with advanced disease. A preliminary study of validity and acceptability. Palliat Med 1995; 9:207-219.
25. Bruera E, KuehnN, MillerMJ, et al.: The Edmonton Symptom Assessment System (ESAS): A simple method for the assessment of palliative care patients. J Palliat Care 1991;7:6-9.
26. Reeve E, Wiese MD, Hendrix I, et al.: Peoples attitudes, beliefs, and experiences regarding polypharmacy and willingness to deprescribe. JAmGeriatr Soc 2013;61:1508-1514.
27. Bashir K, King M, Ashworth M: Controlled evaluation of brief intervention by general practitioners to reduce chronic use of benzodiazepines. Br J Gen Pract 1994;44:408-412.
28. Garfinkel D, Mangin D: Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: Addressing polypharmacy. Arch Intern Med 2010;170:1648-1654.
29. Beer C, Loh P-K, Peng YG, et al.: A pilot randomized controlled trial of deprescribing. Ther Adv Drug Saf 2011; 2:37-43.
30. Reeve E, Shakib S, Hendrix I, et al.: Development and validation of the patients attitudes towards deprescribing (PATD) questionnaire. Int J Clin Pharm 2013;35:51-56.
31. Reeve E, Low LF, Shakib S, Hilmer SN: Development and validation of the revised Patients Attitudes Towards Deprescribing (rPATD) Questionnaire: Versions for older adults and caregivers. Drugs Aging 2016;33:913-928.
32. Qi K, Reeve E, Hilmer SN, et al.: Older peoples attitudes regarding polypharmacy, statin use and willingness to have statins deprescribed in Australia. Int J Clin Pharm 2015;37: 949-957.